News
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
On this week's episode of "The Readout LOUD": a closer look at the NIH’s grant-cutting legal playbook, FDA transparency ...
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S.
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...
With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...
Nearly 1 in 3 American adolescents have prediabetes, a CDC report finds. An official notes "it’s not too late to change ...
The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...
The idea of making the U.S. more like Europe is anathema to many in the Trump administration. But that’s what the Make ...
Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...
The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results